This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Integer (ITGR) Q2 Earnings Miss Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -11.86% and 1.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain momentum from improving non-medical sales and a solid foothold in the broader MedTech space. However, intense competition persists.
Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Integer Holdings (ITGR) Q1 Earnings, Revenues Lag Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) first-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
Integer (ITGR) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -12.36% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer Holdings' (ITGR) Latest Buyout to Expand Its Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) buyout of Aran Biomedical is set to expand its presence in high-growth markets as well as enhance its product offerings.
Integer Holdings (ITGR) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter results reflect robust segmental performances besides strength in the majority of the product lines.
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Integer Holdings (ITGR) Buys Oscor, Boosts Global Footprint
by Zacks Equity Research
Integer Holdings' (ITGR) acquisition of Oscor is likely to bolster its already solid global presence.
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and its focus on growth strategies.
Integer Holdings (ITGR) Beats on Q3 Earnings, Ups 2021 EPS View
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust segmental performances along with strength in the majority of the product lines.
Integer (ITGR) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 9.37% and 0.29%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Retain Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management. However, intense competition is a woe.
3 Promising MedTech Stocks to Snap Up in Second-Half 2021
by Trina Mukherjee
Backed by robust long-term prospects, investors can add three lucrative MedTech stocks, MMSI, ITGR and OFIX, to their watchlist.
Here's Why You Should Invest in Integer Holdings (ITGR) Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to gain traction from portfolio management.
Merit Medical (MMSI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Merit Medical (MMSI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Momentum in Integer (ITGR) Should Keep going
by Zacks Equity Research
Integer (ITGR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Integer (ITGR) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Integer Holdings (ITGR) Beats on Q2 Earnings, Ups 2021 View
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect robust segmental performances along with strength in majority of the product lines.
Integer (ITGR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of 17.58% and 6.68%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks.com featured highlights include: Trinseo, Integer Holdings Corp, Telefonica and Eos Energy
by Zacks Equity Research
Zacks.com featured highlights include: Trinseo, Integer Holdings Corp, Telefonica and Eos Energy
4 Stocks to Keep an Eye on as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the past few weeks might lead to solid price appreciation for stocks like TSE, ITGR, VIV and EOSE.
Integer (ITGR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks
by Zacks Equity Research
Zacks.com featured highlights include: Hibbett, Integer Holdings, Cerevel Therapeutics Holdings and A10 Networks